The goal of the biomarkers working group are to assess biomarkers collected from blood, urine, and tissue samples for their utility in NF clinical trials. Our group works to (1) define biomarker needs and summarize existing data in NF1, NF2, and Schwannomatosis; (2) outline recommendations for sample collection and biomarker development; and (3) standardize sample collection and methodology protocols where possible to promote comparison between studies by publishing standard operating procedures.
Current group co-leaders: Chetan Bettegowda, MD and Oliver Hanemann, MD, PhD, FRCP
Past group leader: Oliver Hanemann, MD, PhD, FRCP
1. Hanemann CO, Blakeley JO, Nunes FP, et al. Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology 2016 Aug 16;87(7 Suppl 1): S40-8. [PDF]